Smallpox future or investigational therapies

Jump to navigation Jump to search

Smallpox Microchapters

Home

Patient Information

Overview

Historical Perspective

Eradication
Post-Eradication

Pathophysiology

Causes

Differentiating Smallpox from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Outbreak Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case Studies

Smallpox future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Smallpox future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Smallpox future or investigational therapies

CDC on Smallpox future or investigational therapies

Smallpox future or investigational therapies in the news

Blogs on Smallpox future or investigational therapies

Directions to Hospitals Treating Smallpox

Risk calculators and risk factors for Smallpox future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Even though smallpox has been eradicated, there are undergoing studies to identify effective antiviral drugs against smallpox virus due to the potential of an outbreak as a result of bioterrorism.

Future or Investigational Therapies

Since the eradication of the smallpox virus, several antiviral drugs have been studied combating orthopox viruses in general, including:[1]

  • Cidofovir
  • Poxvirus protease inhibitors
  • Compounds targeting host's intracellular pathways
  • Currently being studied[6]

References

  1. Moore, Zack S; Seward, Jane F; Lane, J Michael (2006). "Smallpox". The Lancet. 367 (9508): 425–435. doi:10.1016/S0140-6736(06)68143-9. ISSN 0140-6736.
  2. Smee DF, Sidwell RW (2003). "A review of compounds exhibiting anti-orthopoxvirus activity in animal models". Antiviral Res. 57 (1–2): 41–52. PMID 12615302.
  3. Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY (2004). "Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model". Virology. 318 (2): 474–81. doi:10.1016/j.virol.2003.11.015. PMID 14972516.
  4. Quenelle DC, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Kern ER (2004). "Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir". Antimicrob Agents Chemother. 48 (2): 404–12. PMC 321539. PMID 14742188.
  5. Painter GR, Hostetler KY (2004). "Design and development of oral drugs for the prophylaxis and treatment of smallpox infection". Trends Biotechnol. 22 (8): 423–7. doi:10.1016/j.tibtech.2004.06.008. PMID 15283988.
  6. Yang H, Kim SK, Kim M, Reche PA, Morehead TJ, Damon IK; et al. (2005). "Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction". J Clin Invest. 115 (2): 379–87. doi:10.1172/JCI23220. PMC 546427. PMID 15690085.

Template:WH Template:WS